APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials VIENNA and GAITHERSBURG, Md., July 8, 2020 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Oncology, Licensing MaxCyte, APEIRON Biologics, cell therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news